Fmr LLC Increases Position in OPKO Health, Inc. (NASDAQ:OPK)

Fmr LLC grew its position in OPKO Health, Inc. (NASDAQ:OPK) by 103.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,795 shares of the biotechnology company’s stock after purchasing an additional 11,089 shares during the quarter. Fmr LLC’s holdings in OPKO Health were worth $32,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. CIBC Asset Management Inc grew its position in OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 8,978 shares during the last quarter. Algert Global LLC purchased a new position in shares of OPKO Health during the second quarter worth about $44,000. Private Advisor Group LLC grew its holdings in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after buying an additional 25,000 shares during the last quarter. Ground Swell Capital LLC acquired a new position in OPKO Health in the 3rd quarter valued at about $63,000. Finally, Hollencrest Capital Management raised its stake in OPKO Health by 14.0% during the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.51 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a 50 day moving average of $1.54 and a 200-day moving average of $1.48. The firm has a market capitalization of $1.03 billion, a PE ratio of -7.95 and a beta of 1.62. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.76.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This represents a 0.05 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired 1,304,255 shares of company stock valued at $2,024,605 in the last three months. 47.26% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on OPK shares. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th. Finally, StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Thursday.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.